Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain

Nature Chemical Biology

Volumn 12, Issue 11, 2016, Pages 931-936

  Akçay, Gizem ^a   Belmonte, Matthew A ^a   Aquila, Brian ^a   Chuaqui, Claudio ^a   Hird, Alexander W ^a   Lamb, Michelle L ^a   Rawlins, Philip B ^a   Su, Nancy ^a   Tentarelli, Sharon ^a   Grimster, Neil P ^a   Su, Qibin ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORONIC ACID DERIVATIVE; CARBONYL DERIVATIVE; CASPASE 3; CASPASE 7; LYSINE; PROTEIN MCL 1; STAUROSPORINE; MCL1 PROTEIN, HUMAN;

ARTICLE; BIOCHEMICAL ANALYSIS; CATALYSIS; CELL ASSAY; CHEMICAL MODIFICATION; COMPARATIVE STUDY; CONTROLLED STUDY; COVALENT BOND; ENZYME INHIBITION; HUMAN; MEDICINAL CHEMISTRY; NONCATALYTIC LYSINE SIDE CHAIN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLISM; PH; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN-ION CONCENTRATION; LYSINE; MOLECULAR STRUCTURE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84991584281     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2174     Document Type: Article

References (52)

1. Zinzalla, G. & Thurston, D.E. Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Future Med. Chem. 1, 65-93 (2009).
2. Azzarito, V., Long, K., Murphy, N.S. & Wilson, A.J. Inhibition of α-helix-mediated protein-protein interactions using designed molecules. Nat. Chem. 5, 161-173 (2013).
3. Arkin, M.R. & Wells, J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3, 301-317 (2004).
4. Fletcher, S. & Hamilton, A.D. Targeting protein-protein interactions by rational design: mimicry of protein surfaces. J. R. Soc. Interface 3, 215-233 (2006).
5. Arrowsmith, C.H. et al. The promise and peril of chemical probes. Nat. Chem. Biol. 11, 536-541 (2015).
6. Fischer, P.M. Protein-protein interactions in drug discovery. Drug Design Reviews Online 2, 179-207 (2005).
7. Way, J.C. Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs. Curr. Opin. Chem. Biol. 4, 40-46 (2000).
8. Singh, J., Petter, R.C., Baillie, T.A. & Whitty, A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10, 307-317 (2011).
9. Tummino, P.J. & Copeland, R.A. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47, 5481-5492 (2008).
10. Hajduk, P.J. Fragment-based drug design: how big is too big? J. Med. Chem. 49, 6972-6976 (2006).
11. Kuntz, I.D., Chen, K., Sharp, K.A. & Kollman, P.A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. USA 96, 9997-10002 (1999).
12. Dutta, S. et al. Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL. J. Mol. Biol. 398, 747-762 (2010).
13. Smith, A.J.T., Zhang, X., Leach, A.G. & Houk, K.N. Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. J. Med. Chem. 52, 225-233 (2009).
14. Copeland, R.A., Pompliano, D.L. & Meek, T.D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5, 730-739 (2006).
15. Walter, A.O. et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 3, 1404-1415 (2013).
16. Rudolph, J. & Stokoe, D. Selective inhibition of mutant Ras protein through covalent binding. Angew. Chem. Int. Ed. Engl. 53, 3777-3779 (2014).
17. Basu, D., Richters, A. & Rauh, D. Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR. Bioorg. Med. Chem. 23, 2767-2780 (2015).
18. Finlay, M.R.V. et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem. 57, 8249-8267 (2014).
19. Barf, T. & Kaptein, A. Irreversible protein kinase inhibitors: balancing the benefits and risks. J. Med. Chem. 55, 6243-6262 (2012).
20. Lee, C.U. & Grossmann, T.N. Reversible covalent inhibition of a protein target. Angew. Chem. Int. Ed. Engl. 51, 8699-8700 (2012).
21. Serafimova, I.M. et al. Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles. Nat. Chem. Biol. 8, 471-476 (2012).
22. Choi, S., Connelly, S., Reixach, N., Wilson, I.A. & Kelly, J.W. Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma. Nat. Chem. Biol. 6, 133-139 (2010).
23. Anscombe, E. et al. Identification and characterization of an irreversible inhibitor of CDK2. Chem. Biol. 22, 1159-1164 (2015).
24. Cal, P.M.S.D. et al. Iminoboronates: a new strategy for reversible protein modification. J. Am. Chem. Soc. 134, 10299-10305 (2012).
25. Bandyopadhyay, A., McCarthy, K.A., Kelly, M.A. & Gao, J. Targeting bacteria via iminoboronate chemistry of amine-presenting lipids. Nat. Commun. 6, 6561 (2015).
26. Verdine, G.L. & Walensky, L.D. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 13, 7264-7270 (2007).
27. Cory, S. & Adams, J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2, 647-656 (2002).
28. Czabotar, P.E., Lessene, G., Strasser, A. & Adams, J.M. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15, 49-63 (2014).
29. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
30. Wei, G. et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 21, 547-562 (2012).
31. Wenzel, S.S. et al. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia 27, 1381-1390 (2013).
32. Yancey, D. et al. BAD dephosphorylation and decreased expression of MCL-1 induce rapid apoptosis in prostate cancer cells. PLoS One 8, e74561 (2013).
33. Palve, V., Mallick, S., Ghaisas, G., Kannan, S. & Teni, T. Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers. PLoS One 9, e111927 (2014).
34. Williams, M.M. & Cook, R.S. Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance? Oncotarget 6, 3519-3530 (2015).
35. Ashkenazi, A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 7, 1001-1012 (2008).
36. Yamanaka, K. et al. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol. Cancer Ther. 4, 1689-1698 (2005).
37. Cohen, N.A. et al. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem. Biol. 19, 1175-1186 (2012).
38. Muppidi, A. et al. Rational design of proteolytically stable, cell-permeable peptide-based selective Mcl-1 inhibitors. J. Am. Chem. Soc. 134, 14734-14737 (2012).
39. Tanaka, Y. et al. Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins. J. Med. Chem. 56, 9635-9645 (2013).
40. Friberg, A. et al. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J. Med. Chem. 56, 15-30 (2013).
41. AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma. https://clinicaltrials.gov/ct2/show/NCT02675452.
42. Bruncko, M., Song, X., Ding, H., Tao, Z.F. & Kunzer, A.R. 7-nonsubstituted indole mcl-1 inhibitors. WO Patent 2008130970 A1 filed 28 April 2008, and issued 2 March 2016.
43. Bruncko, M. et al. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity. J. Med. Chem. 58, 2180-2194 (2015).
44. Belmonte, M.A. et al. Evaluation of Mcl-1 inhibitors in preclinical models of multiple myeloma. Blood 124, 3428 (2014).
45. Touzeau, C. et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia 30, 761-764 (2016).
46. Booher, R.N. et al. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis. PLoS One 9, e108371 (2014).
47. Cal, P.M.S.D., Frade, R.F.M., Cordeiro, C. & Gois, P.M.P. Reversible lysine modification on proteins by using functionalized boronic acids. Chemistry 21, 8182-8187 (2015).
48. Mah, R., Thomas, J.R. & Shafer, C.M. Drug discovery considerations in the development of covalent inhibitors. Bioorg. Med. Chem. Lett. 24, 33-39 (2014).
49. Belmar, J. & Fesik, S.W. Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol. Ther. 145, 76-84 (2015).
50. Mukherjee, H. et al. Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 mediate the cellular localization of nucleophosmin and its AML-associated mutants. ACS Chem. Biol. 10, 855-863 (2015).
51. Kenny, P.W. & Sadowski, J. Structure modification in chemical databases. in Chemoinformatics in Drug Discovery (ed., T.I. Oprea) Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, FRG) 271-285 (2005).
52. Gasteiger, J., Rudolph, C. & Sadowski, J. Automatic generation of 3D-atomic coordinates for organic molecules. Tetrahedron Computer Methodology 3, 537-547 (1990).